Device Trial Radar · NCT05303467
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jul 30, 2022
Primary completion
Jan 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions
- Glioblastoma Multiforme
- Recurrent Glioblastoma
Interventions
TheraSphere GBMDevice
Single treatment of TheraSphere GBM device
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of grade 3-5 non-hematological toxicitiesTime frame: 30 days post index procedure
- The number of ≥ grade 3 CNS toxicities related to non-target embolizationTime frame: 30 days post index procedure
- Occurrence of symptomatic brain radiation necrosis requiring medical or surgical intervention and confirmed by pathologyTime frame: 30 days post index procedure
3 more outcomes with a free account
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama · Withdrawn
University of California San Diego
San Diego, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.